Given investment horizon of 30 days, Nektar Therapeutics is expected to under-perform the Biopath. But the stock apears to be less risky and, when comparing its historical volatility, Nektar Therapeutics is 3.04 times less risky than Biopath. The stock trades about -0.17 of its potential returns per unit of risk. The Biopath Holdings Inc is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest 29.00 in Biopath Holdings Inc on April 26, 2012 and sell it today you would earn a total of 8.00 from holding Biopath Holdings Inc or generate 27.59% return on investment over 30 days.
Diversification
Significant diversification
Overlapping area represents amount of risk that can be diversified away by holding Nektar Therapeutics and Biopath Holdings Inc in the same portfolio (assuming nothing else is changed)
91% of all equities and portfolios perform better than Biopath Holdings Inc. Compared with the overall equity markets, risk-adjusted returns on investments in Biopath Holdings Inc are ranked lower than 9 (%) of all global equities and portfolios over the last 30 days.
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
